# US 2006/0078544 A1 · Novel cancer-associated antigens and methods of their identification and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078544 A1
- Document ID: US20060078544A1
- Status: Published application
- Kind: A1
- Application number: 11/274,856
- Filed: 2005-11-16
- Published: 2006-04-13
- Earliest claimed: 1998-11-03
- Assignees: Cell Genesys, Inc.
- Inventors: James McArthur; Ju-Fay Chang; Dale Ando; Margo Roberts; Jonathan Simons; William Nelson
- Web page: https://patentgrep.com/patent/US20060078544A1

## CPC

- G01N 33/57555: of the prostate
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- G01N 33/575: for cancer
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine and proliferation-incompetent tumor cells which express the tumor-associated antigen. Also provided are kits for carrying out the methods of the invention.

## Claims

### Claim 1

A method for generating an enhanced immune response to a prostate tumor associated antigen comprising,
administering to a subject a composition comprising cancer cells that have been rendered proliferation-incompetent and have been genetically engineered to express GM-CSF, wherein following said administering a humoral immune response to a prostate tumor-associated antigen is detected, wherein said humoral immune response is not detected prior to said administering and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein said prostate tumor-associated antigen has a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, as detected by SDS-PAGE.

### Claim 3 (depends on 1)

The method of claim 1, wherein said proliferation-incompetent tumor cells are autologous.

### Claim 4 (depends on 1)

The method of claim 1, wherein said proliferation-incompetent tumor cells are allogeneic.

### Claim 5 (depends on 4)

The method of claim 4, wherein said proliferation-incompetent tumor cells are LnCaP or PC3 cells.

### Claim 6 (depends on 4)

The method of claim 4, wherein said proliferation-incompetent tumor cells are LnCaP and PC3 cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 8 (depends on 7)

The method of claim 7, wherein said human subject has prostate cancer.

### Claim 9 (depends on 1)

The method of claim 1, wherein said composition is administered intradermally, intramuscularly, or subcutaneously via injection.

### Claim 10 (depends on 9)

The method of claim 9, wherein said composition is administered intradermally.

### Claim 11

A method for treating prostate cancer, comprising:
administering to a subject a composition comprising cancer cells that have been rendered proliferation-incompetent and have been genetically engineered to express GM-CSF, wherein following said administering a humoral immune response to a prostate tumor-associated antigen is detected, wherein said humoral immune response is not detected prior to said administering and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

### Claim 12 (depends on 11)

The method of claim 11, wherein said prostate tumor-associated antigen has a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, as detected by SDS-PAGE.

### Claim 13 (depends on 11)

The method of claim 11, wherein said proliferation-incompetent tumor cells are autologous.

### Claim 14 (depends on 11)

The method of claim 11, wherein said proliferation-incompetent tumor cells are allogeneic.

### Claim 15 (depends on 14)

The method of claim 14, wherein said proliferation-incompetent tumor cells are LnCaP or PC3 cells.

### Claim 16 (depends on 14)

The method of claim 14, wherein said proliferation-incompetent tumor cells are LnCaP and PC3 cells.

### Claim 17 (depends on 11)

The method of claim 11, wherein said subject is a human.

### Claim 18 (depends on 17)

The method of claim 17, wherein said human subject has prostate cancer.

### Claim 19 (depends on 11)

The method of claim 11, wherein said composition is administered intradermally, intramuscularly, or subcutaneously via injection.

### Claim 20 (depends on 19)

The method of claim 19, wherein said composition is administered intradermally.

### Claim 21

A method for generating an enhanced immune response to a prostate tumor associated antigen comprising,
administering to a subject a composition comprising GM-CSF-expressing non-cancerous cells and proliferation-incompetent tumor cells, wherein following said administering a humoral immune response to a prostate tumor-associated antigen is detected, wherein said humoral immune response is not detected prior to said administering and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

### Claim 22 (depends on 21)

The method of claim 21, wherein said prostate tumor-associated antigen has a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, as detected by SDS-PAGE.

### Claim 23 (depends on 21)

The method of claim 21, wherein said proliferation-incompetent tumor cells are autologous.

### Claim 24 (depends on 21)

The method of claim 21, wherein said proliferation-incompetent tumor cells are allogeneic.

### Claim 25 (depends on 24)

The method of claim 24, wherein said proliferation-incompetent tumor cells are LnCaP or PC3 cells.

### Claim 26 (depends on 24)

The method of claim 24, wherein said proliferation-incompetent tumor cells are LnCaP and PC3 cells.

### Claim 27 (depends on 21)

The method of claim 21, wherein said subject is a human.

### Claim 28 (depends on 27)

The method of claim 27, wherein said human subject has prostate cancer.

### Claim 29 (depends on 21)

The method of claim 21, wherein said composition is administered intradermally, intramuscularly, or subcutaneously via injection.

### Claim 30 (depends on 29)

The method of claim 29, wherein said composition is administered intradermally.

### Claim 31

A method for treating prostate cancer, comprising:
administering to a subject a composition comprising GM-CSF-expressing non-cancerous cells and proliferation-incompetent tumor cells, wherein following said administering a humoral immune response to a prostate tumor-associated antigen is detected, wherein said humoral immune response is not detected prior to said administering and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

### Claim 32 (depends on 31)

The method of claim 31, wherein said prostate tumor-associated antigen has a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, as detected by SDS-PAGE.

### Claim 33 (depends on 31)

The method of claim 31, wherein said proliferation-incompetent tumor cells are autologous.

### Claim 34 (depends on 31)

The method of claim 31, wherein said proliferation-incompetent tumor cells are allogeneic.

### Claim 35 (depends on 34)

The method of claim 34, wherein said proliferation-incompetent tumor cells are LnCaP or PC3 cells.

### Claim 36 (depends on 34)

The method of claim 34, wherein said proliferation-incompetent tumor cells are LnCaP and PC3 cells.

### Claim 37 (depends on 31)

The method of claim 31, wherein said subject is a human.

### Claim 38 (depends on 37)

The method of claim 37, wherein said human subject has prostate cancer.

### Claim 39 (depends on 31)

The method of claim 31, wherein said composition is administered intradermally, intramuscularly, or subcutaneously via injection.

### Claim 40 (depends on 39)

The method of claim 39, wherein said composition is administered intradermally.
